TW202327608A - 治療病毒感染的方法 - Google Patents

治療病毒感染的方法 Download PDF

Info

Publication number
TW202327608A
TW202327608A TW111135154A TW111135154A TW202327608A TW 202327608 A TW202327608 A TW 202327608A TW 111135154 A TW111135154 A TW 111135154A TW 111135154 A TW111135154 A TW 111135154A TW 202327608 A TW202327608 A TW 202327608A
Authority
TW
Taiwan
Prior art keywords
days
rho
protein kinase
kinase inhibitor
compound
Prior art date
Application number
TW111135154A
Other languages
English (en)
Chinese (zh)
Inventor
鄭翔玲
趙焰平
王紅軍
周麗瑩
仲偉婷
柴棟
何伊欣
侯翠柳
Original Assignee
北京泰德製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京泰德製藥股份有限公司 filed Critical 北京泰德製藥股份有限公司
Publication of TW202327608A publication Critical patent/TW202327608A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111135154A 2021-09-17 2022-09-16 治療病毒感染的方法 TW202327608A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111096047 2021-09-17
CN202111096047.9 2021-09-17

Publications (1)

Publication Number Publication Date
TW202327608A true TW202327608A (zh) 2023-07-16

Family

ID=85602458

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111135154A TW202327608A (zh) 2021-09-17 2022-09-16 治療病毒感染的方法

Country Status (3)

Country Link
CN (1) CN118019530A (fr)
TW (1) TW202327608A (fr)
WO (1) WO2023041024A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2969536T3 (es) * 2017-06-30 2024-05-21 Beijing Tide Pharmaceutical Co Ltd Inhibidor de la proteína cinasa asociada a rho, composición farmacéutica que lo comprende, y su método de preparación y uso
WO2019000682A1 (fr) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Inhibiteur de protéine kinase associée à rho, composition pharmaceutique contenant celui-ci, son procédé de préparation et ses applications
TWI804743B (zh) * 2019-06-25 2023-06-11 大陸商北京泰德製藥股份有限公司 治療特發性肺纖維化的方法
KR20230061444A (ko) * 2020-08-31 2023-05-08 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Rho-연관 단백질 인산화효소 억제제의 염, 염의 고체 형태, 이의 제조 방법 및 이의 용도
CA3209240A1 (fr) * 2021-02-22 2022-08-25 Samuel D. Waksal Inhibiteur de rock2 pour le traitement d'une infection virale

Also Published As

Publication number Publication date
CN118019530A (zh) 2024-05-10
WO2023041024A1 (fr) 2023-03-23

Similar Documents

Publication Publication Date Title
AU2020200903B2 (en) Compositions and methods for treating anemia
AU2021253796B2 (en) Compounds and methods for the treatment of COVID-19
KR101591701B1 (ko) 저산소증 유발 인자-1 알파의 안정화 증가 방법
TWI804743B (zh) 治療特發性肺纖維化的方法
WO2020177587A1 (fr) Méthode de traitement d'une stéatose hépatique et/ou d'une stéatohépatite
CA2862193C (fr) Composition anti-tuberculose contenant des composes a base d'oxazole
TWI404529B (zh) 神經再生及／或保護劑
CN110637022B (zh) 可作为流感病毒复制抑制剂的吡咯并嘧啶衍生物
JP2023530316A (ja) 貧血の治療のためのａｌｋ２阻害剤
TW202304914A (zh) 經取代之四環羧酸、其類似物及使用其之方法
WO2017146236A1 (fr) Médicament pour le traitement du cancer caractérisé par l'administration d'une association d'un inhibiteur de l'axl et d'un inhibiteur de point de contrôle immunitaire
US20230019280A1 (en) Substituted isoindolonyl 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same
WO2023041024A1 (fr) Procédé de traitement d'infections virales
WO2022017412A1 (fr) Méthode de traitement d'une maladie du greffon contre l'hôte provoquée par une transplantation de cellules souches hématopoïétiques
WO2022143610A1 (fr) Nouveaux composés d'amide pyrrole et leur utilisation dans des médicaments
WO2023226822A1 (fr) Procédé d'utilisation d'un dérivé d'azétidine pour traiter des infections virales et utilisation
WO2024078592A1 (fr) Médicament ciblant une protéine d'activation des fibroblastes et son utilisation
US20230255933A1 (en) Antiviral use of fabp4 modulating compounds
US20230241025A1 (en) Antiviral use of fabp4 modulating compounds
US20230078120A1 (en) Methods for Treating Coronavirus Infections
WO2024078553A1 (fr) Procédé de traitement de la pneumoconiose
TW202345849A (zh) 以iap拮抗劑化合物治療癌症之方法及組合療法
AU2014290012B2 (en) Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers